Several easy methods will be used to study how blood vessels change in middle-aged people. These methods include heating a small spot on the arm, using a small TENS unit, using an ultrasound with a blood pressure cuff on the arm, and taking a blood sample.

There will be 2 in-person visits, one will be ~1 hour, the other will be ~2. We will take a blood sample at each visit. The second visit will require you to be seated and resting the entire time.

75

This research study aims to address a gap in the current literature by focusing on technology acceptance and usage factors among minority elderly individuals. The overall goal of this study is to find the perceived barriers and reasons for the digital healthcare divide within the minority elderly population in respects to patient portals.

All participants will be required to review an informed consent form prior to starting the survey or interview. Participants will be screened for eligibility criteria via questions on their age, race, and if they reside in the United States. If they meet the study's inclusion criteria, they will be able to complete the survey and/or interview focusing on electronic patient portals and demographic questions, along with data privacy, security, and data governance questions regarding patient portals.

This is an exploratory sequential mixed methods study that will explore the extent to which the barriers of diagnostic delay in Black women with endometriosis are generalizable to the general endometriosis population. There will be two phases of this study: a qualitative phase followed by a quantitative phase. The qualitative phase will involve semi-structured interviews with Black women who have a confirmed endometriosis diagnosis. The findings from the qualitative phase will be used to modify a questionnaire for the quantitative phase of the study. The quantitative phase will be a short questionnaire, taken by endometriosis patients of any racial/ethnic background with a confirmed diagnosis.

Participants will be asked to complete a 15 minute online questionnaire about their experiences with receiving an endometriosis diagnosis. Questions will include demographic information, endometriosis history, and perceptions of barriers that contributed to a delayed diagnosis.

$10

This study is trying to understand more about factors that cause pain in people who have had experiences of discrimination.

2 in-person visits 3-4 hours each plus at-home online questionnaires In-person visits will involve: 1. Sensory and pain testing 2. Physical function testing 3. Blood draw 4. MRI scan 5. Questionnaires

Up to $250

The purpose of this study is to evaluate the effectiveness and safety of navenibart as a preventative treatment for people with Type I or Type II Hereditary Angioedema (HAE).

You will need to come to Penn State Health Milton S. Hershey Medical Center 8 times. You will answer questions about your health/HAE attacks, provide blood samples, undergo routine urine laboratory tests, receive the trial drug, undergo electrocardiogram (ECG), complete questionnaires, undergo physical exams, and provide HAE attack information.

A sample repository for the examination of biomarkers for Amyotrophic Lateral Sclerosis (ALS) and other Motor Neuron Diseases

Participants will be asked to donate blood one or more times and provide age, sex and general history of neurological disease. ALS/motor neuron disease patients will be asked to release information from the medical record about their neurological disorder, strength, function, treatments, known pathogenic ALS-related gene variants, quality of life, and results of breathing tests.

The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy and usual chemotherapy plus the chemotherapy drug lomustine (Gleostine). Lomustine (Gleostine) is already approved by the FDA for use in brain tumors but it is usually used alone and is not the first-line choice for methylated MGMT tumors.

• Group 1 If you are in this group, you will get the usual approach used to treat this type of cancer (radiation plus temozolomide, followed by temozolomide alone). You will receive radiation plus temozolomide for about 6 weeks. During this time, you will receive radiation 5 days per week and temozolomide every day. Beginning about 1 month after you finish radiation, you will receive temozolomide for 5 days in a row every 4 weeks for up to 6 months. You will get temozolomide as a pill you take by mouth. After radiation, you may receive the Optune device if you and your treating physician decide it is best for you. There will be about 153 people in this group. • Group 2 If you are in this group, you will get the usual treatment of radiation 5 days per week for 6 weeks with the chemotherapy drugs lomustine (Gleostine) and temozolomide.. You will get both lomustine (Gleostine) and temozolomide as pills you take by mouth. After radiation, you may receive the Optune device if you and your treating physician decide it is best for you. There will be about 153 people in this group.

This trial will examine the outcome of comparing Sonrotoclax Plus Zanubrutinib vs. Zanubrutinib alone in the treatment of mantle cell lymphoma

Participants must come to all study visits, take the medication as instructed, tell the study how you are feeling and tell the study team about any medications you are taking, especially over the counter medications.

This study is for participants who have a brain tumor and decide with their doctor to use GammaTile radiation therapy to treat their brain tumor. This treatment is FDA approved. The purpose of this study is to collect data on how this treatment impacts your health and wellbeing.

There are no required visits or treatments for this study. At your regularly scheduled doctor visits, your study doctor or staff will enter relevant health and medical information into the study database. You will also be asked to complete questionnaires about the quality of your life during your routine medical appointments.

Each participant will have a maximum study participation of 61 weeks, which includes a total duration of study treatment approximately 52 weeks: Period 1 (double-blind, placebo-controlled treatment; 16 weeks) and Period 2 (double-blind, active treatment; 36 weeks). At different timepoints throughout the study subjects will have their skin examined, have labs drawn, have an ECG perfomed, as well as answer questionnaires.

Study participation will last approximately 56 weeks. During the study, participants will attend 20 in person visits in the research office. At different timepoints the participant will have their skin examined, blood drawn, have an ECG done, answer questionnaires and take study medication as directed by the study team.

Older and younger adults may differ in how they comprehend language. Here we plan to EEG of word and sentence processing to understand differences in how older and younger adults use context to form predictions.

There will be a single, 2-hour visit in which your 'brain waves' are recorded while you read words. We will also ask you to complete pencil and paper tasks and computer tasks to learn more about how your brain works.

$30

The purpose of this study is to measure Event Free Survival (EFS) with IL cemiplimab (investigational intervention) compared with primary surgery for participants who have an eligible CSCC (cutaneous squamous cell carcinoma) that is great than or equal to 1 to less than or equal to 2 cm in the longest diameter. The maximum length that a participant will be on study is approximately 3 years. Participants will be assigned 2 to 1 to either the experimental arm or the control arm.

The maximum length that a participant will be on study is approximately 3 years. Visit Frequency: - Experimental Arm: Every week for 6 treatment visits. There is a clinical visit for TL assessment on Week 8. Assessment of response at the TL site occurs at week 13. -Control Arm: 1 day for surgery, with post-surgical visits at week 3 and week 13 -Both Arms: Week 19, then every 3 months for years 1 and 2, and every 4 months for year 3. Additional visits may occur for clinical issues that may arise, per standard of care. At different timepoints throughout the study participants will have their skin examined and photographed, answers questionnaires/interview, have blood drawn, and have a biopsy.

We know that both what (e.g., apples, pizza) and how (e.g., large vs small bites, fast vs slow) can contribute to overeating. The study will be focused on how children eat. We want to see if children eat the same way in the lab as they eat at home. We will assess laboratory and home eating styles (e.g., bite rate) in 100 prepubertal 6-9-year-old children. Children will be video-recorded while consuming identical study-provided meals at home and in the laboratory in addition to a ‘typical’ meal at home.

Healthy 6-9 year-olds and their parents are needed for the MEAL-TIME Study at Penn State University. We are looking for children to help us learn about how kids respond to different types of foods and computer games. The study consists of 3 visits to our facilities in Noll and Chandlee Labs, located on the University Park Campus. Your child will eat a meal and complete computer game tasks at each visit. Between visits, you will be asked to record your child eating at home using a study-provided smart phone. Your child will also complete an IQ test. Some children may experience anxiety when completing clinical procedures (e.g., height, weight). You and your child will be compensated $50 per visit for a total of $150. Each visit is expected to be 1.5 hours long and at-home meal recordings are expected to take 30-45 min, for a total of 8 hours participating in our lab.

$150

The purpose of this research study is 1.) to determine if Parkinson’s Disease (PD) causes changes in the way that people sense the movements of and forces produced by their bodies, and to connect any of these changes in sensation to changes in the brain, and 2.) to identify how changes in movement might come from different parts of the nervous system. This study will use a combination of electromyography, via electrodes placed on the skin, and finger force recordings to infer how PD affects patients' sense of force production, and the neural mechanisms underlying this change.

Participants will complete a phone screen, then attend one in-person visit at Penn State Health. During the visit, they will perform finger-pressing tasks, have surface electrodes placed on their skin to record muscle activity, complete motor and memory assessments, and fill out questionnaires.

40

This study is loking at how a new drug treats breast cancer. The breast cancer must have the following genetic mutations BRCA1, 2 or PALB2

You will need to come to all the study visits, take the study medication as prescribed, tell the study doctor about all medications you are taking, including over the counter and to tell the doctor how you are feeling.

AHOD2131:A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab. This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma.

Consent to treatment, required labs and imaging, sample collections, and completion of research study tests and surveys and/or questionnaires.

This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.

Consent to treatment, required labs, sample collections, and completion of research study tests and surveys and/or questionnaires.

This phase 3 trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it.

Consent to treatment, required labs, sample collections, and completion of research study tests and surveys and/or questionnaires.

To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of CTCAE Grade 3 or higher immune related adverse events (irAEs).

Consent to treatment, required labs, imaging, and sample collections.

Primary Aims: 1. To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available Phase I/II PedAL sub-trials. 2. To maintain a longitudinal and comprehensive registry from relapse in children and young adults with recurrent and refractory leukemia.

Consent to enrollment, required labs and sample collections.

The next generation of therapy for childhood cancers will be based upon in-depth molecular phenotyping that may facilitate the development of rational risk-adapted and target-based therapies. In order to support current and future molecularly-guided therapeutic trials and the basic science discovery efforts that will lead to more effective therapies, prevention, early detection and a reduction in early and late-onset toxicities, it is critical to implement universal, high-quality collection of annotated biospecimens from children with cancer. This protocol provides for the collection of biospecimens and accompanying demographic, epidemiologic, therapeutic, and outcome data from all children diagnosed with cancer at participating COG institutions, independent of the patient’s enrollment on a therapeutic clinical trial. Through this approach, the correlation of phenotypic and genotypic or other –omic data with the relevant outcomes at the individual, disease, and protocol levels will be ensured. Biospecimen requirements and handling may be disease specific and thus a detailed manual of procedures will provide disease specific information regarding sample collection and processing based on the clinical diagnosis.

Consent to enrollment, eligibility screening and sample collections.

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.

Consent to treatment, required labs, sample collections, and completion of research study tests and surveys and/or questionnaires.

The study involves taking the drug levocarnitine during standard of care chemotherapy. The overall goal of this study is to determine whether taking levocarnitine will reduce the rate of severe liver damage caused by asparaginase chemotherapy during the first month of treatment.

Consent to treatment, required labs, sample collections, and completion of surveys.

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).

Consent to treatment, required labs, sample collections, and imaging.

Umbrella Long Term Follow Up Protocol (COG ALTE05N1)

Consent to enrollment and eligibility screening and completion of surveys and/or questionnaires.

This Phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without harming normal cells.

Consent to treatment, required labs, sample collections, and completion of research study tests.

How does the brain decide to reach one way or the other? This study will examine how movement decisions are coordinated by neural mechanisms in the brain during manual interception and reaching actions.

Participants will be required to complete a simple virtual interception task with a handle. Participants will be screened and sign informed consent upon entry of the lab. They will then be fitted with EMG sensors and an eye-tracking reference sticker. They will be seated for this task. The task requires a participant to hold their hand steady at the epicenter of a circle, and reach as quickly and accurately as possible to one of 2 moving targets that will appear.

$20

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

Consent to treatment, required labs, sample collections, and completion of research study tests and surveys and/or questionnaires.

The overall goal of this study is to compare the effects, good and/or bad, of two different surgery methods for people with OST that has spread to the lung to find out which is better. In this study, participants will receive 1 of 2 treatment plans. Treatment with open surgery is the older standard therapy for people with OST that has spread to the lung. Treatment with VATS is a newer method that has also been shown to work when used to treat the same type of cancer

Consent to treatment, required labs, sample collections, and completion of research study tests and surveys and/or questionnaires.

This phase II trial studies how well irinotecan hydrochloride (irinotecan), temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back or that isn't responding to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as dinutuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Eflornithine blocks the production of chemicals called polyamines that are important in the growth of cancer cells. Giving eflornithine with irinotecan hydrochloride, temozolomide, and dinutuximab, may work better in treating patients with relapsed or refractory neuroblastoma.

Consent to treatment, required labs, sample collections, and completion of research study tests and surveys and/or questionnaires.